Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SSR240600C · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| SSR240600C Dose Level 1 | EXPERIMENTAL | - |
| SSR240600C Dose Level 2 | EXPERIMENTAL | - |
| SSR240600C Dose Level 3 | EXPERIMENTAL | dose level 3 |
| Tolterodine | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| SSR240600C | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SSR240600C | DRUG | oral administration |
| tolterodine | DRUG | oral administration |
| placebo | DRUG | oral administration |
Inclusion Criteria: * Diagnosis of overactive bladder Exclusion Criteria: * Stress incontinence or mixed incontinence where stress incontinence is the predominant component based on prior history * Urinary incontinence due to cause other than detrusor overactivity (eg, overflow incontinence) * Cu...
SSR240600C is an investigational small molecule being developed by Sanofi for the treatment of overactive bladder. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being studied in female patients with overactive bladder or urge urinary incontinence.
SSR240600C is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker SNY. The drug is currently in Phase 2 clinical trials for overactive bladder, and it remains an investigational compound that has not yet received regulatory approval.
SSR240600C is in Phase 2 clinical development. Two Phase 2 trials have been completed, both of which were randomized, double-blind, and placebo-controlled studies in female patients with overactive bladder. The drug is investigational and has not been approved by the FDA or other regulatory agencies.
SSR240600C has been studied in two completed Phase 2 clinical trials. The first, NCT00174798, enrolled 118 female patients in the United States. The second, NCT00564226, enrolled 345 female patients across the United States, Canada, Czechia, France, Germany, Netherlands, and Portugal. Both trials were randomized, double-blind, and placebo-controlled.
SSR240600C is the drug studied in the MILADY trial, which is the clinical trial identified as NCT00174798. The trial was titled 'MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.' SSR240600C is the investigational compound evaluated in this study.